Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

NCT05485909 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Liver Metastases

Interventions

OTHER: Radiofrequency ablation
DRUG: Regorafenib and Toripalimab Combination

Sponsor

Sun Yat-sen University